---

Neuromuscular Junction: Anatomy, Physiology, Anaesthetic Pharmacology, Factors Affecting Blockade & Monitoring

---

PART 1: ANATOMY OF THE NEUROMUSCULAR JUNCTION

Structural Components

• The axon of the alpha-motor neuron loses its myelin sheath as it approaches the muscle and terminates in a bulb-shaped nerve ending
• The nerve terminal contains mitochondria (energy supply), choline acetyltransferase (CAT), and numerous synaptic vesicles
• Each vesicle contains approximately 5,000-10,000 molecules of ACh stored as "quanta"
• Vesicle membrane proteins: synaptophysin (glycoprotein), synaptotagmin (Ca2+ sensor), synapsin (vesicular trafficking), synaptobrevin/VAMP (SNARE protein for membrane fusion)
• Voltage-gated Ca2+ channels and K+ channels are present on the presynaptic membrane
• Active zones - specialized release sites directly opposite postjunctional receptor clusters

• Width: 50-70 nm
• Contains acetylcholinesterase (AChE) embedded in the basement membrane - this enzyme rapidly hydrolyzes ACh into choline + acetic acid
• Choline is recycled back into the presynaptic terminal via a sodium-linked active transporter

• The muscle membrane is thrown into junctional folds (secondary clefts), which increase surface area
• Nicotinic acetylcholine receptors (nAChR) are concentrated at the crests of these folds at high density (~10,000 receptors/µm²)
• Deep in the folds: voltage-gated Na+ channels responsible for propagating the muscle action potential
• The NMJ occupies only 0.1% of the total muscle surface area

---

PART 2: PHYSIOLOGY OF NEUROMUSCULAR TRANSMISSION

Steps in Neuromuscular Transmission

The Nicotinic Acetylcholine Receptor (nAChR)

Safety Margin of Neuromuscular Transmission

• ACh released (~200 quanta) greatly exceeds the minimum needed
• ~500,000 receptors are activated per nerve impulse
• Only a small fraction of available vesicles/receptors are used per signal
• ~70-80% of receptors must be blocked before any clinical weakness is apparent
• >90-95% must be blocked for complete paralysis (detectable by TOF count = 0)

Miniature End-Plate Potentials (MEPPs)

• Spontaneous, random release of single ACh quanta at rest
• Amplitude ~1/100 of evoked EPP - too small to trigger action potential
• First described by Fatt & Katz (1952) - established the quantal theory of ACh release

Post-Tetanic Potentiation (PTP)

• High-frequency nerve stimulation → Ca2+ accumulates in nerve terminal (enters faster than it can be extruded)
• The nerve terminal is transiently "calcium-loaded" → increased ACh release on subsequent stimuli
• Clinically: after tetanic stimulation during NDMR blockade, the next single twitch is temporarily augmented (post-tetanic count)

---

PART 3: ANAESTHETIC PHARMACOLOGY OF NEUROMUSCULAR BLOCKING DRUGS

Classification

Neuromuscular Blocking Drugs
├── Depolarizing
│   └── Succinylcholine (suxamethonium)
└── Non-depolarizing (NDMRs)
    ├── Benzylisoquinoliniums
    │   ├── Short: Mivacurium
    │   ├── Intermediate: Atracurium, Cisatracurium
    │   └── Long: d-Tubocurarine, Pancuronium, Doxacurium
    └── Aminosteroids
        ├── Intermediate: Vecuronium, Rocuronium
        └── Long: Pancuronium

---

A. DEPOLARIZING MUSCLE RELAXANTS - SUCCINYLCHOLINE

• Continuous depolarization keeps perijunctional Na+ channels in the inactivated state (voltage-gated Na+ channels cannot reopen during sustained depolarization)
• Manifests as: initial fasciculations → sustained paralysis
• Characteristics:
  • TOF: fade absent (all 4 twitches equally depressed)
  • Tetanic stimulation: no fade, no PTP
  • Not reversed by anticholinesterases (neostigmine worsens it)
  • Potentiated by: volatile agents, prior NDMR administration

• Occurs with large or repeated doses of succinylcholine (>4-6 mg/kg cumulative)
• The receptor shifts to a "desensitized" state despite depolarization
• Characteristics:
  • TOF: fade present (resembles NDMR block)
  • Tetanic stimulation: fade present + PTP present
  • May be partially reversible with neostigmine
  • Mechanism: receptor phosphorylation, ion channel block, receptor desensitization

• Dose: 1-1.5 mg/kg IV (children: 1.5-2 mg/kg; infants up to 3 mg/kg)
• Onset: 60-90 seconds
• Duration: 5-10 minutes (shortest-acting NMBD)
• Metabolism: rapidly hydrolyzed by plasma (pseudo)cholinesterase (butyrylcholinesterase) in plasma - NOT at the NMJ itself
• Metabolites: succinylmonocholine → succinic acid + choline (inactive)

• Dibucaine (local anaesthetic) inhibits normal pseudocholinesterase by ~80%, but inhibits atypical enzyme by only ~20%
• Neostigmine also inhibits pseudocholinesterase - avoid succinylcholine immediately after neostigmine

1. Hyperkalaemia - K+ rises ~0.5 mEq/L normally; can be catastrophic in burns (>48h), prolonged immobilization, upper/lower motor neuron injuries, crush injuries (due to upregulated extrajunctional receptors)
2. Bradycardia - especially with repeated doses; due to muscarinic receptor stimulation
3. Fasciculations - may cause myalgia, increased IOP, ICP, and intragastric pressure
4. Malignant hyperthermia - succinylcholine is a potent MH trigger
5. Masseter muscle spasm - may herald MH
6. Increased IOP - contraindicated in open eye injury
7. Anaphylaxis - most common drug cause of anaphylaxis in anaesthesia

---

B. NON-DEPOLARIZING MUSCLE RELAXANTS (NDMRs)

• TOF: fade (T4 < T1, TOF ratio < 1.0)
• Tetanic stimulation: fade + post-tetanic potentiation (PTP)
• Reversed by anticholinesterases (neostigmine, edrophonium, pyridostigmine)
• Reversed by sugammadex (aminosteroid NDMRs only)

• Pancuronium: vagolytic (tachycardia, hypertension) - blocks muscarinic receptors
• Atracurium: histamine release (hypotension, tachycardia) at rapid/high doses
• Vecuronium, rocuronium, cisatracurium: essentially cardiovascularly neutral

---

C. REVERSAL AGENTS

• Must always be given with glycopyrrolate (with neostigmine/pyridostigmine) or atropine (with edrophonium) to prevent muscarinic side effects
• Most effective when TOF ratio >0.1-0.2 (i.e., at least 2-3 twitches present)
• Cannot effectively reverse deep block - must wait for spontaneous partial recovery
• Neostigmine also inhibits pseudocholinesterase → prolongs succinylcholine and mivacurium

• Modified gamma-cyclodextrin that encapsulates aminosteroid NDMRs (rocuronium > vecuronium >> pancuronium) in a 1:1 complex
• Works at any depth of block - unique advantage over anticholinesterases
• Doses:
  • Routine reversal (TOF≥2): 2 mg/kg
  • Deep block (PTC 1-2): 4 mg/kg
  • Immediate reversal (RSI, 3 min post-rocuronium 1.2 mg/kg): 16 mg/kg
• Does NOT affect muscarinic receptors - no need for anticholinergic pretreatment
• Key interactions: may affect hormonal contraceptives (progestogen binding) - advise alternative contraception for 7 days

---

PART 4: FACTORS AFFECTING NEUROMUSCULAR BLOCKADE

A. Patient-Related Factors

• Neonates/Infants: Higher sensitivity to NDMRs per unit muscle mass but higher volume of distribution → doses on mg/kg basis similar to adults. Succinylcholine dose higher (1.5-2 mg/kg in children, 2-3 mg/kg in infants). Immature nAChRs with gamma subunits resistant to NDMRs but sensitive to depolarizing drugs.
• Elderly: Reduced cardiac output → slower onset. Reduced renal/hepatic function → prolonged duration of renally/hepatically eliminated drugs. Decreased muscle mass.

• Myasthenia Gravis: Autoimmune destruction of postjunctional nAChRs → profound sensitivity to NDMRs (reduce dose by 50-75%), resistance to succinylcholine
• Lambert-Eaton Myasthenic Syndrome: Antibodies against presynaptic voltage-gated Ca2+ channels → sensitivity to both NDMRs and depolarizing agents; augmented with repeated stimulation (unlike MG)
• Muscular Dystrophies: Avoid succinylcholine (rhabdomyolysis risk)
• UMN/LMN lesions (>24h): Upregulated extrajunctional receptors → life-threatening hyperkalaemia with succinylcholine; resistance to NDMRs

• Respiratory acidosis (↑ pCO2): Potentiates NDMR block, impairs reversal
• Metabolic alkalosis: Potentiates NDMR block
• Metabolic acidosis: Antagonizes some NDMR block

• Hypokalaemia: Potentiates NDMR block (widens resting membrane potential, more negative)
• Hypercalcaemia: Antagonizes NDMR block (increases ACh release)
• Hypocalcaemia: Potentiates NDMR block
• Hypomagnesaemia: Antagonizes (Mg2+ competes with Ca2+ at presynaptic Ca2+ channels → decreases ACh release)
• Hypermagnesaemia: Potentiates NDMR block significantly
• Lithium: Potentiates both depolarizing and non-depolarizing block

• Hypothermia: Potentiates NDMR block (reduces hepatic/renal metabolism, slows Hofmann elimination, reduces protein binding, shifts ACh quantal content)

• Acute phase (<48h): Sensitive to NDMRs (loss of receptor-rich membrane)
• Post-acute phase (>48h): AVOID succinylcholine (hyperkalaemia from upregulated extrajunctional receptors); resistant to NDMRs

B. Drug Interactions

---

PART 5: MONITORING OF NEUROMUSCULAR BLOCKADE

Why Monitor?

• NDMRs do not alter consciousness - a paralyzed patient may be awake
• Residual paralysis occurs in 30-40% of patients reversed with neostigmine
• Clinical assessment is inadequate: even 5-second head lift can be performed at TOF ratio <0.5
• Guidelines from multiple countries (Canada, France, UK, Australia, Japan, USA) now mandate quantitative monitoring

Nerve Stimulation - Basic Principles

• Electrode placement: negative electrode distal, positive electrode proximal
• Alternative sites: facial nerve → orbicularis oculi; peroneal nerve → foot

Patterns of Stimulation

1. Single Twitch (ST)

• Single supramaximal stimulus at 0.1-1 Hz
• Compares response to a baseline (control) twitch
• Can detect 75-80% receptor occupancy before significant depression
• Not useful for monitoring depth of block without a pre-block control

2. Train-of-Four (TOF) - Most Commonly Used

• Normal = 1.0
• <0.9: Residual paralysis - associated with postoperative respiratory complications
• <0.7: Significant weakness (unable to sustain 5-second head lift in some patients)
• <0.4: Unable to maintain airway, severe hypoventilation

• NDMRs block presynaptic α3β2 nAChRs (which normally mobilize ACh vesicles with repetitive stimulation)
• With repeated stimuli, fewer ACh quanta are released → T4 < T3 < T2 < T1
• This presynaptic block is the basis of fade with NDMRs

3. Tetanic Stimulation

• Sustained stimulation at 50 Hz (5 s) or 100 Hz (2 s)
• Sustained tetanus = no residual NDMR blockade
• Fade during tetanus = NDMR block present
• Post-tetanic potentiation (PTP): twitch augmented for 1-2 minutes after tetanic stimulation due to Ca2+ accumulation in nerve terminal
• Should NOT be used repeatedly - painful, can unmask residual block (PTP confounds subsequent TOF)

4. Post-Tetanic Count (PTC)

• Used in deep block when TOF count = 0 and no single twitches visible
• Apply tetanic stimulation (50 Hz, 5s) → wait 3 seconds → count number of single twitches (1 Hz)
• PTC 1-2 = very deep block; PTC 5-10 = deep block recovering; PTC >10 = first TOF twitch about to return

5. Double Burst Stimulation (DBS)

• Two short bursts of 50 Hz tetanic stimulation separated by 750 ms
• DBS₃,₃: 3 pulses at 50 Hz, 750 ms gap, 3 pulses at 50 Hz
• The ratio of second burst to first burst correlates with TOF ratio
• More sensitive than TOF for detecting residual fade by tactile/visual assessment - fade detectable at lower levels of block
• Useful when TOFR is 0.6-0.9 (tactile fade in TOF is unreliable in this range)

Quantitative Monitoring Modalities

Differential Muscle Sensitivity to NDMR Block

Residual Neuromuscular Blockade

• Defined as TOFR < 0.9 at the time of tracheal extubation
• Incidence: ~30-40% with neostigmine reversal alone; ~5% with sugammadex
• Consequences: impaired hypoxic ventilatory response, pharyngeal dysfunction (aspiration risk), upper airway obstruction, critical respiratory events in PACU
• Neither clinical signs nor time from last dose are reliable predictors
• Quantitative monitoring is the only reliable method to rule out residual paralysis

---

Summary Table: Key Points for MD Anaesthesia Exam

---